Skip to main content
Springer logoLink to Springer
. 2024 Feb 16;35(1):84–87. doi: 10.1007/s12022-024-09804-5

Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment

C Christofer Juhlin 1,
PMCID: PMC10944430  PMID: 38363524

Case History

A male in his early thirties, without any prior medical history, presented with a history of fatigue. Upon examination, mild hypercalcemia and elevated levels of parathyroid hormone (PTH) were observed. The patient was subsequently referred to our endocrine surgery department. Ultrasound and sestamibi scintigraphy revealed an enlarged right superior parathyroid gland measuring 20 mm. The patient had no family history suggestive of parathyroid disease or MEN1-related manifestations. A focused parathyroidectomy was performed.

What Is Your Diagnosis?

Figure composites (see Figs. 1 and 2).

Fig. 1.

Fig. 1

Morphological indicators of parafibromin deficiency in a parathyroid tumor. A This hypercellular parathyroid gland was composed of eosinophilic cells (right) intermingled with focal areas with chief cells (left). Note the absence of stromal fat. There were no atypical histological features associated to malignancy. B Eosinophilic cells exhibited perinuclear clearing. C Focal microcystic change. D Areas with arborizing vasculature within the tumor tissue are a recurrent finding in parafibromin-deficient parathyroid tumors

Fig. 2.

Fig. 2

Immunohistochemical staining outcome. A PTH immunoreactivity was diffusely positive, thereby confirming the parathyroid origin and indicating the retained antigenicity of the sample. B Strong nuclear expression of parafibromin was evident in the normal parathyroid rim. C Eosinophilic tumor cells were parafibromin-deficient, exhibiting negative nuclear staining along with a granular cytosolic stain, interpreted as aberrant (× 100 magnification). D High-power (× 400) magnification of the parafibromin stain

Diagnosis: Parafibromin-Deficient Parathyroid Adenoma

During gross examination, the weight was 1.1 g. The gland measured 20 × 15 × 7 mm and displayed a brownish cut surface. No macroscopic features indicative of malignancy, such as a grey/white cut surface or unclear relations to the surroundings, were observed. The entire tumor was submitted for microscopic evaluation.

Histology revealed a hypercellular parathyroid gland characterized by chief cells arranged in microacinar patterns and solid areas containing eosinophilic cells (Fig. 1A). The stromal fat content was diminished. Notably, there was a general absence of mitotic activity and tumor necrosis. The tumor was circumscribed, and invasive growth was not observed. No atypical histological features such as trabecular growth, fibrous bands, or prominent nuclear pleomorphism were noted. Upon closer examination, the eosinophilic cells exhibited a distinct pinkish cytoplasm but lacked the characteristic cytoplasmic granularity of oxyphilic cells (Fig. 1B). Additionally, these cells showed perinuclear cytoplasmic clearing (“halo”). Some regions also displayed microcystic features and arborizing vasculature (Fig. 1C, D). These morphological features have been associated with parafibromin-deficient parathyroid tumors [1]. Tumor cells were positive for PTH and APC but negative for galectin-3 and PGP9.5 (Fig. 2A). The Ki-67 index was low (2.4%). Parafibromin exhibited positive staining in cells at the tumor margin and in the majority of chief cells (Fig. 2B). However, the nuclear stain was negative in the eosinophilic cell component, displaying a vague, granular cytosolic stain, interpreted as aberrant (Fig. 2C, D).

The favored diagnosis was a parafibromin-deficient parathyroid adenoma, and the patient was found to harbor a pathogenic CDC73 gene mutation involving the nuclear localization signal of parafibromin.

Comment

When pathologists discuss parafibromin, it is typically in the context of diagnosing an atypical parathyroid tumor or parathyroid carcinoma, as these conditions are more frequently associated with CDC73 gene mutations compared to parathyroid adenomas [2, 3]. However, this case illustrates how morphological indicators can guide pathologists to order relevant immunohistochemical stainings, assisting the clinical team in identifying a potential syndromic case even in a benign scenario. In our clinical practice, immunohistochemistry is not routinely applied to screen parathyroid adenomas. Recognizing sheet-like eosinophilic tumor cells with a perinuclear halo and associated arborizing vasculature could therefore be important, offering endocrine pathologists a valuable genotype–phenotype correlation [1].

Speculatively, the identified CDC73 mutation could potentially disrupt the nuclear localization of parafibromin, leading to its sequestration in the cytosolic compartment. Previous studies have demonstrated a crucial role for nuclear parafibromin to function as a tumor suppressor, implying that CDC73 mutations in the NLS sequence could be pathogenic [4]. Similarly, parafibromin possesses a nucleolar localization signal (NoLS), and the loss of nucleolar parafibromin has been linked to CDC73 mutations within the NoLS region [5]. Therefore, meticulous microscopic examination at high magnification is essential when evaluating parafibromin.

Author Contributions

C.C.J. wrote the manuscript text and prepared the figures.

Funding

Open access funding provided by Karolinska Institute. The author is indebted to the financial support provided by the Swedish Cancer Society.

Availability of Data and Materials

The author confirms that the data supporting the findings of this study are available within the article.

Declarations

Ethical Approval

Ethical approval was granted by the Swedish Ethical Review Authority, and written informed consent was obtained from the patient.

Competing Interests

The authors declare no competing interests.

Footnotes

The  case with associated descriptions was previously shown during a slide seminar entitled “The lesson hidden in a single case” during the 2023 European Congress of Pathology in Dublin, Ireland.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Gill AJ, Lim G, Cheung VKY, Andrici J, Perry-Keene JL, Paik J, Sioson L, Clarkson A, Sheen A, Luxford C, Elston MS, Meyer-Rochow GY, Nano MT, Kruijff S, Engelsman AF, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Marsh DJ, Toon CW, Chou A, Clifton-Bligh RJ. Parafibromin-deficient (HPT-JT Type, CDC73 mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol. 2018 doi: 10.1097/PAS.0000000000001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol. 2022;33:64–89. doi: 10.1007/s12022-022-09709-1. [DOI] [PubMed] [Google Scholar]
  • 3.Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol. 2021;32:17–34. doi: 10.1007/s12022-020-09656-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hahn MA, Marsh DJ. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene. 2005;24:6241–6248. doi: 10.1038/sj.onc.1208778. [DOI] [PubMed] [Google Scholar]
  • 5.Juhlin CC, Haglund F, Obara T, Arnold A, Larsson C, Höög A. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch. 2011;459:47–53. doi: 10.1007/s00428-010-1032-3. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The author confirms that the data supporting the findings of this study are available within the article.


Articles from Endocrine Pathology are provided here courtesy of Springer

RESOURCES